XOMA doesn't want to toil in anonymity. Instead, the company pairs with larger drug firms to develop and market its products, primarily monoclonal antibodies (biotech drugs based on cloned proteins). The firm partners on therapeutics for cancer, infectious disease, inflammatory ailments, and autoimmune conditions; it also receives royalties on drugs developed by companies that have licensed its technologies. XOMA has collaborative agreements with companies and entities such as Takeda Pharmaceutical, Merck, and the National Institutes of Health (to find treatments for bioterrorism threat botulinum). In addition, the company has some proprietary candidates for metabolic and oncology applications.